Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- 3 Top-Ranked Consumer ETFs to Buy Now
- This Week's Top Value Stocks
- RTI: When Will We Finally See a Pullback?
- RTI: When is the Fed's "Taper Telegraph" Coming?
- Insurance Industry Stock Outlook - May 2013
- Top Stocks with Big Potential Catch-Up Moves
- Roundtable Top Picks of the Week
- Anatomy of Success: Green Mountain Coffee
- The Mega-Rally Rolls On
- Biotechnology ETF Investing 101
- AWS 5/21: The Beginning of the End for QE
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/21/2013
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Brian Marckx, CFA
Q1 2011 Financial Results...
Chembio ( CEMI ) reported financial results for the first quarter ending March 31, 2011 on May 5, 2011. Revenue of $3.64 million was about 8% below our $3.94 million estimate. The difference due to lower than modeled product sales ($3.02MM versus $3.72MM estimate), partially offset by higher R&D contracts and milestone revenue ($592MM versus $225MM estimate). The miss in product sales relative to our estimate was mostly a result of significantly lower than modeled sales of DPP tests to FIOCRUZ. However, domestic sales of the lateral flow tests to Allere remained very strong in the quarter. Coming in at $2.1MM, U.S. lateral flow sales grew 77% y-o-y and 18% sequentially.
EPS was $0.00, in-line with our estimate. Despite the lower than modeled revenue figure, net loss came in at $142k, slightly better than our $254k figure as a result of significant improvement in gross margin. Gross margin of 53% was driven by an impressive 43% product margin (product margin has historically run in the 35% - 38% range). Margins benefitted from a greater percentage of sales coming the U.S. market. Operating expenses were largely in-line with our estimates.
Cash...
Cash flow from operations was $1.6 million in the quarter, which included $2.23 million from collections of accounts receivable, mostly reflecting large shipments made during December 2010. Chembio exited the quarter with $2.8 million in cash and equivalents, up from $2.1 million at the end of 2010. In January 2011 the final $875k due Bio-Rad under the HIV-2 licensing agreement was made. Chembio also noted that just over $200k was raised through the exercise of stock options (@ $0.40 strike) in April. We continue to expect Chembio to be able to manage to fund all operations (including clinical trials, regulatory filings, SG&A, etc.) through cash on hand and funds from operations.
For a free copy of the full research report, please email scr@zacks.com with CEMI as the subject.
Follow Zacks Small Cap Research on Twitter at Twitter.com/ZacksSmallCap
Read the full reports :
on CEMI